Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanoViricides, Inc. Signs Rabies Agreement with CDC for Expanded Research

Abstract:
Study to Evaluate Usage Strategy for further Development towards Drug Approval

NanoViricides, Inc. Signs Rabies Agreement with CDC for Expanded Research

WEST HAVEN, CT | Posted on August 4th, 2008

NanoViricides, Inc. (OTC BB: NNVC.OB), (the "Company") said that it has signed a Materials Cooperative Research and Development Agreement (MCRADA) with the United States Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia for rabies treatment study. The study, to be performed in collaboration with the CDC Rabies Program, is scheduled to begin soon.

"This study will expand on two successful animal studies of RabiCide™-I performed previously by the government of Vietnam," said Eugene Seymour, MD, MPH, CEO of the Company, adding that "In those prior studies we achieved a 25% to 30% survival rate in animals that had already developed rabies. We believe this strong survival rate is a historical first achievement for any post-infection rabies treatment."

"Collaborating with CDC in designing and conducting these studies is an important step forward," said Anil R. Diwan, PhD, President of the Company, adding, "If the current studies are successful, we anticipate that this will be instrumental in helping our anti-rabies nanoviricide towards drug approval and widespread use across the world."

The Company has previously reported that Yale Research Professor Thomas Lentz, a leading expert in antiviral therapeutics based on virus-cell binding, has joined the Scientific Advisory Board. Prof. Lentz studied the binding of rabies virus to various cell receptors and has performed pioneering research in this field. The Company believes that it has put together a strong team to tackle rabies.

About the Centers for Disease Control and Prevention (CDC):

The Centers for Disease Control and Prevention is an organization that protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing creditable information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations. As a federal agency, CDC does not promote or endorse specific products or entities. For more information please visit www.cdc.gov.

About Rabies:

Rabies is a uniformly fatal disease (i.e. 100% death rate upon infection), and cannot be cured after infection occurs, except in very rare cases. Rabies is transmitted to humans upon getting bitten by mammals such as bats and canines (dogs, raccoons, foxes, etc.). The World Health Organization estimates that more than 55,000 people die each year from rabies, mostly in Asia, Africa and Latin America. An estimated 10 million people receive prophylactic treatment against rabies due to exposure to potentially rabid animals. Rabies is a viral zoonotic (infectious disease transmitted by animals to humans) neuroinvasive disease that causes acute encephalitis (inflammation of the brain) in mammals. There are only six known survivors of clinical rabies. For more information please visit www.cdc.gov/rabies.

Rabies prophylaxis and treatment market worldwide is estimated to be well in excess of $300 million.

####

About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC (epidemic kerato-conjunctivitis or severe pink eye disease), hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Designing ultrasound tools with Lego-like proteins August 29th, 2016

A nanoscale wireless communication system via plasmonic antennas: Greater control affords 'in-plane' transmission of waves at or near visible light August 27th, 2016

Forces of nature: Interview with microscopy innovators Gerd Binnig and Christoph Gerber August 26th, 2016

A promising route to the scalable production of highly crystalline graphene films August 26th, 2016

Govt.-Legislation/Regulation/Funding/Policy

Analog DNA circuit does math in a test tube: DNA computers could one day be programmed to diagnose and treat disease August 25th, 2016

New approach to determining how atoms are arranged in materials August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

New electrical energy storage material shows its power: Nanomaterial combines attributes of both batteries and supercapacitors August 25th, 2016

Announcements

Designing ultrasound tools with Lego-like proteins August 29th, 2016

A nanoscale wireless communication system via plasmonic antennas: Greater control affords 'in-plane' transmission of waves at or near visible light August 27th, 2016

Forces of nature: Interview with microscopy innovators Gerd Binnig and Christoph Gerber August 26th, 2016

A promising route to the scalable production of highly crystalline graphene films August 26th, 2016

Alliances/Trade associations/Partnerships/Distributorships

Thomas Swan and NGI announce unique partnership July 28th, 2016

Starpharma initiates new DEP™ drug delivery program with AstraZeneca July 27th, 2016

XEI Scientific Partners with Electron Microscopy Sciences to Promote and Sell its Products in North and South America July 25th, 2016

Leti and Korea Institute of Science and Technology to Explore Collaboration on Advanced Technologies for Digital Era July 14th, 2016

Research partnerships

New electrical energy storage material shows its power: Nanomaterial combines attributes of both batteries and supercapacitors August 25th, 2016

New theory could lead to new generation of energy friendly optoelectronics: Researchers at Queen's University Belfast and ETH Zurich, Switzerland, have created a new theoretical framework which could help physicists and device engineers design better optoelectronics August 23rd, 2016

A new way to display the 3-D structure of molecules: Metal-organic frameworks provide a new platform for solving the structure of hard-to-study samples August 21st, 2016

Researchers watch catalysts at work August 19th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic